ClinicalTrials.gg
SuspendedNCT04530305MARAJAUpdated Oct 26, 2026

Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

An observational study in Rheumatoid Arthritis, sponsored by University Hospital, Montpellier. Suspended at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Hospital, Montpellier · Observational

How we know

Why this study was suspended
Evolution of treatment sequencing for JAK inhibitors
Updated Oct 26, 2026Now SuspendedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.

Planned enrollment
10th of 12
60 · median 182
Started
2021
with 4 others
Observational
12 of 27
3 open now
Registered
15th of 27
by date

Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2021, is one of 12 observational ones, and was the 15th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, or all of them as a file.
02

Study summary

Personalized medicine in which each patient would receive the ideal personalized treatment and regimen, holds great promise to improve patient's care. However, previous studies failed to establish validated predictors of response to disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). JAK inhibitors is a new class of DMARDs with great efficacy that might be even superior to anti-TNF drugs. As there are chemicals, their production cost is much cheaper than biological therapies and they will probably be central in patient's care in the coming years. Three are currently available: upadacitinib (UPA) tofacitinib and baricitinib. Our study will focus on UPA. Clinical outcomes mainly depend on i) factors influencing drug metabolism \& concentrations and ii) adequacy between drug target and the inflammation pathways involved in the patient's disease. Humans carry in their gut trillions of germs, which are now known to be key players in health and disease. Those germs possess many enzymes and strongly modulate human enzymes expression. Gut-microbiota can, indeed, directly metabolize oral drugs and control the expression of the cytochrome P450 3A4 (CYP3A4), the main enzyme metabolizing TOFA. We showed, in a preliminary mouse experiment, that modifying gut-microbiota composition changes JAKi effects on signaling pathways. We thus believe that models including gut-microbiota composition together with markers of immune activation will predict clinical outcomes in RA patients treated with UPA.

Main and secondary objectives: To build predictive models for clinical outcomes (efficacy and safety) of RA patients treated with UPA based on microbiota analysis and markers f immune activation.

Methodolgy:

This multicentric longitudinal prospective study will include 60 patients with RA and inadequate response to methotrexate. The clinical outcomes studied will be EULAR non-response at 3 months as defined by the European league against rheumatism EULAR (primary outcome), achievement of low-disease activity at 6 months or incident adverse events (secondary outcomes). Gut microbiota will be assessed at baseline and M3 from thawed fecal samples. DNA will be purified using QIAamp DNA stool mini kit (Qiagen) and qualify using Qubit and TapeStation 4200 (Agilent). Library will be prepared by amplification of V1-V2 and V3-V4 regions from the bacterial 16S rRNA genes and will be qualified by q-PCR and amplicons will be sequenced by MiSeq (Illumina). Initial bioinformatic analysis and taxonomies will be carried out using the QIIME2 software. Immune activation will be assessed through JAK-STAT pathway activation by JAK STAT signaling pathway RT² profiler PCR Array (Qiagen) which profiles expression of 84 genes related to Jak and Stat-mediated signaling. UPA concentrations will be assessed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) at baseline and 3 months. Statistical classifiers (Neural network algorithm, Linear and Quadratic Discriminant Analysis, Support Vector Machine, Random forests, Shrinkage Methods, or Nearest Neighbors) incorporating microbiome, JAK STAT signaling pathway gene expression and clinical data, will be used to determine profiles associated with UPA clinical response and safety. Patients who will prematurely stop UPA (before 3 months) for adverse events or loss of follow-up will be considered as non-responders.

Read the detailed description

Gut microbiota is becoming an important predictor of response and tolerance with anti-cancer drugs. However, its potential of prediction in other fields has poorly been explored.

Drug metabolism and concentrations of tofacitinib depend on body mass index, liver function and cytochrome P450 activity (especially CYP3A4). Humans carry in their gut trillions of germs, which are now known to be key players in health and disease. Those germs can strongly impact drug metabolism and concentrations based on 3 mechanisms. First, gut bacteria possess a huge pool of enzymes which catalyzes drug metabolism reactions. Second, gut microbiota regulates bile acid metabolism which play critical role in drug metabolism. Third, gut microbiota modulates the expression of cytochrome P450, especially CYP3A4, the main enzyme catabolizing Tofacitinib (TOFA).

In addition to drug metabolism, gut microbiota is a key driver of immune activation. Clinical response to CTLA-4 or anti-PD-1 strongly depends on gut microbiota in different cancers. The experiments performed to decipher the mechanisms involved suggested that microbiota composition affects immune responses, which will facilitate or not anti-tumoral efficacy of checkpoints inhibitors.

RA is a heterogeneous disease with predominant inflammation pathways varying dependent on patients. Some RA seem to be more dependent on IL-6 whereas others rely more on TNF-alpha, B or T cells. Gut microbiota was shown to affect all those different targets. Assessing baseline levels of JAK STAT signaling pathway gene expression will help us to link immune activation, gut microbiota and clinical response to UPA.

We hypothesize that gut-microbiota composition impacts JAKi metabolism, immune activation, and thus clinical response and has a great potential to predict clinical outcomes in patients with RA treated with UPA.

Study objectives :

  1. Main objective

    To construct a model based on gut-microbiota composition, immune activation markers (JAK-STAT signalling pathway) and clinical data to predict UPA non-response at 3 months in RA patients with inadequate response to methotrexate.

  2. Secondary objectives

    • To construct a model based on gut-microbiota composition, immune activation markers (JAK-STAT signalling pathway) and clinical data to predict low-disease activity at 6 months of UPA in RA patients with inadequate response to methotrexate.
    • To compare responders and non-responders and patients with or without adverse effects on UPA in terms of:

      • baseline gut-microbiota
      • UPA concentrations at 3 months
      • baseline JAK-STAT signalling pathway gene expression profile
      • baseline clinical data
    • To correlate changes in disease activity score based on 28 joint evaluation (DAS28, see annex for calculation) between month-3 and baseline with:

      • changes in gut microbiota
      • UPA concentrations
      • changes in JAK-STAT signaling
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with RA fulfilling American College of Rheumatology (ACR)/ European league against rheumatism (EULAR) 2010 criteria with inadequate response to MTX for who a treatment with UPA will be prescribed in standard care to control disease activity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with RA fulfilling American College of Rheumatology (ACR)/ European league against rheumatism (EULAR) 2010 criteria
  • Patients with inadequate response to MTX
  • Patients receiving MTX as therapy or will receive UPA as monotherapy

Exclusion criteria

Exclusion Criteria:

  • Patients with to upadacitinib
  • Patients previously treated with biological DMARDs or JAK inhibitors
  • Patients treated with ≥ 10 mg/day of
  • Use of IV glucocorticoids in the previous month
  • Previous use of biological DMARDs (TNF inhibitors, rituximab, abatacept, tocilizumab) or JAK inhibitors
  • Absence of
  • Pregnancy planned for the duration of the study, Women pregnant or breastfeeding women
  • Major protected by law or patient under guardianship
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • DrugUpadacitinibStudies of UpadacitinibUpadacitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.

06

What researchers measure

Primary outcomes

  1. EULAR response

    Response will be defined following European league against rheumatism EULAR definition that is a decrease \>0.6 points of Disease-Activity-Score 28-joints (DAS28-CRP) and a DAS28-CRP≤5.1 at 3 months . Patients who will prematurely stop UPA (before 3 months) for adverse events, RA flair or loss of follow-up will be considered as non-responders.

    Time frame: 3 months

Secondary outcomes

  1. EULAR good response

    EULAR good-response at 3 and 6 months: DAS28-CRP≤3.2 and deltaDAS28 (M0-M3)\>1.2

    Time frame: 3 and 6 months

  2. Achievement of low-disease activity:

    DAS28-CRP at 6 months \<3.2 and/or DAS28-ESR at 6 months \<3.2

    Time frame: 6 months

  3. Adverse events

    Incidence, relatedness, and severity of treatment-emergent SUSARs, SAEs, ARs and AEs will be evaluated continuously. Patients with adverse events occurring between study visits will be asked to contact the study center for AE reporting.

    Time frame: during the 6 month follow-up

  4. Baseline gut-microbiota

    microbiota will be described in terms of alpha and beta diversity, phylum, genus, OTU.

    Time frame: baseline, 3 and 6 months

  5. UPA concentrations

    Time frame: 0, 3 and 6 months

  6. Baseline JAK-STAT signalling pathway gene expression profile

    gene expression profile will include the level of expression of 84 genes

    Time frame: baseline

  7. Baseline clinical data

    DAS28-CRP, body-mass index, age and gender

    Time frame: baseline

07

Study locations

1 site
  • CHU de Montpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in Sep 2026, 68 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Apr 2024 → Sep 2026 and completion Oct 2024 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2020
First posted
Aug 28, 2020
StartActual
Jan 7, 2021
Primary completionActual
Sep 16, 2026was Apr 2024
CompletionEst.
May 16, 2027was Oct 2024
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended Evolution of treatment sequencing for JAK inhibitors
changed Oct 26, 2026
Primary completion
Apr 2024→Sep 16, 2026 (actual)
Oct 26, 2026
Study completion
Oct 2024→May 16, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Suspended
    Why stopped Evolution of treatment sequencing for JAK inhibitors
    Primary completion Apr 2024→Sep 16, 2026 (now actual)
    Study completion Oct 2024→May 16, 2027
    + 5 other changes: index terms, identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04530305
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Jan 7, 2021
Primary completion
Sep 16, 2026
Completion
May 16, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Claire DAIEN, Prof
principal investigator · Montpellier Hospital and University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion